195 related articles for article (PubMed ID: 34707147)
1. FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab.
Kawashima A; Yamamoto Y; Sato M; Nakata W; Kakuta Y; Ishizuya Y; Yamaguchi Y; Yamamoto A; Yoshida T; Takayama H; Takada T; Inoue H; Okuda Y; Kato T; Hatano K; Uemura M; Nonomura N; Imamura R
Sci Rep; 2021 Oct; 11(1):21199. PubMed ID: 34707147
[TBL] [Abstract][Full Text] [Related]
2. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
[TBL] [Abstract][Full Text] [Related]
3. Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
Palacka P; Slopovsky J; Obertova J; Chovanec M; Rejlekova K; Sycova-Mila Z; Kollarik B; Mardiak J; Mego M
Anticancer Res; 2021 Nov; 41(11):5749-5759. PubMed ID: 34732448
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.
Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S
Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892
[TBL] [Abstract][Full Text] [Related]
5. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
[TBL] [Abstract][Full Text] [Related]
6. Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma.
Kurashina R; Ando K; Inoue M; Izumi K; Maruyama R; Mitani K; Takenobu H; Haruta M; Iizuka T; Kamijo T; Kageyama Y
Anticancer Res; 2022 Feb; 42(2):1131-1136. PubMed ID: 35093916
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis.
Yanagisawa T; Mori K; Katayama S; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Motlagh RS; Aydh A; König F; Grossmann NC; Pradere B; Miki J; Kimura T; Egawa S; Shariat SF
Int J Clin Oncol; 2022 Jan; 27(1):59-71. PubMed ID: 34757531
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of the FAN Score, a Combination of the Fibrosis-4 Index, Albumin-Bilirubin Score and Neutrophil-Lymphocyte Ratio, in Patients Hospitalized with Heart Failure.
Maeda D; Kanzaki Y; Sakane K; Tsuda K; Akamatsu K; Hourai R; Okuno T; Tokura D; Hasegawa H; Sakaguchi K; Ito T; Hoshiga M
Int Heart J; 2022; 63(6):1121-1127. PubMed ID: 36450551
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of multiple hematological biomarkers as prognostic predictors of survival in bladder cancer.
Zhang L; Li L; Liu J; Wang J; Fan Y; Dong B; Zhu Z; Zhang X
Medicine (Baltimore); 2020 Jul; 99(30):e20920. PubMed ID: 32791672
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma.
Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
Cancer Immunol Immunother; 2022 Jan; 71(1):229-236. PubMed ID: 34100985
[TBL] [Abstract][Full Text] [Related]
11. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies.
Wu S; Zhao X; Wang Y; Zhong Z; Zhang L; Cao J; Ai K; Xu R
Cell Physiol Biochem; 2018; 46(4):1352-1364. PubMed ID: 29689562
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.
Ito K; Kobayashi T; Kojima T; Hikami K; Yamada T; Ogawa K; Nakamura K; Sassa N; Yokomizo A; Abe T; Tsuchihashi K; Tatarano S; Inokuchi J; Tomida R; Fujiwara M; Takahashi A; Matsumoto K; Shimizu K; Araki H; Kurahashi R; Osaki Y; Tashiro Y; Uegaki M; Ogawa O; Kitamura H; Nishiyama H
Cancer Med; 2021 May; 10(10):3188-3196. PubMed ID: 33931987
[TBL] [Abstract][Full Text] [Related]
14. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
Cantiello F; Russo GI; Vartolomei MD; Farhan ARA; Terracciano D; Musi G; Lucarelli G; Di Stasi SM; Hurle R; Serretta V; Busetto GM; Scafuro C; Perdonà S; Borghesi M; Schiavina R; Cioffi A; De Berardinis E; Almeida GL; Bove P; Lima E; Ucciero G; Matei DV; Crisan N; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Mirone V; Shariat SF; Ferro M
Eur Urol Oncol; 2018 Oct; 1(5):403-410. PubMed ID: 31158079
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer.
Petrova MP; Eneva MI; Arabadjiev JI; Conev NV; Dimitrova EG; Koynov KD; Karanikolova TS; Valev SS; Gencheva RB; Zhbantov GA; Ivanova AI; Sarbianova II; Timcheva CV; Donev IS
Biosci Trends; 2020 Mar; 14(1):48-55. PubMed ID: 32023563
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
[TBL] [Abstract][Full Text] [Related]
17. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
18. Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Isobe T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Nozaki S; Iida K; Noda Y; Shimizu N; Tomiyama N; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
Int J Clin Oncol; 2022 Jan; 27(1):165-174. PubMed ID: 34633579
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Chen S; Zhang N; Wang T; Zhang E; Wang X; Zheng J
Front Immunol; 2020; 11():1900. PubMed ID: 32983112
[TBL] [Abstract][Full Text] [Related]
20. Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma.
Nagai T; Naiki T; Isobe T; Sugiyama Y; Etani T; Iida K; Nozaki S; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Banno R; Kubota H; Hamamoto S; Kawai N; Yasui T
In Vivo; 2021; 35(5):2793-2800. PubMed ID: 34410970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
